These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29385739)

  • 41. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
    Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
    Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
    Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy.
    Chen X; Li J; Chen Y; Que Z; Du J; Zhang J
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.
    Mahadevia H; Uson Junior PLS; Wang J; Borad M; Babiker H
    Expert Opin Pharmacother; 2024; 25(1):79-90. PubMed ID: 38193476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in immunotherapy for pancreatic ductal adenocarcinoma.
    Miyazawa M; Katsuda M; Kawai M; Hirono S; Okada KI; Kitahata Y; Yamaue H
    J Hepatobiliary Pancreat Sci; 2021 May; 28(5):419-430. PubMed ID: 33742512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Facts and Hopes in Immunotherapy of Pancreatic Cancer.
    Bockorny B; Grossman JE; Hidalgo M
    Clin Cancer Res; 2022 Nov; 28(21):4606-4617. PubMed ID: 35775964
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects.
    Li KY; Yuan JL; Trafton D; Wang JX; Niu N; Yuan CH; Liu XB; Zheng L
    Chronic Dis Transl Med; 2020 Mar; 6(1):6-17. PubMed ID: 32226930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
    Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
    Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Challenges in Cancer Treatment.
    Zugazagoitia J; Guedes C; Ponce S; Ferrer I; Molina-Pinelo S; Paz-Ares L
    Clin Ther; 2016 Jul; 38(7):1551-66. PubMed ID: 27158009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
    Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
    Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
    Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
    Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
    Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination immunotherapy for pancreatic cancer: challenges and future considerations.
    Gössling GCL; Zhen DB; Pillarisetty VG; Chiorean EG
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1173-1186. PubMed ID: 36045547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
    Foucher ED; Ghigo C; Chouaib S; Galon J; Iovanna J; Olive D
    Front Immunol; 2018; 9():1044. PubMed ID: 29868007
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.
    Heumann T; Azad N
    Cancer Metastasis Rev; 2021 Sep; 40(3):837-862. PubMed ID: 34591243
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
    Mempel TR; Krappmann D
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies.
    Pham TND; Shields MA; Spaulding C; Principe DR; Li B; Underwood PW; Trevino JG; Bentrem DJ; Munshi HG
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Application of PD-1 Blockade in Cancer Immunotherapy.
    Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
    Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
    Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
    Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.